Antiplatelet and Anticoagulation Therapies

The Medicines Company announced an agreement July 9 with Sandoz Inc. for the distribution of an authorized generic of Angiomax (bivalirudin) for injection in the United States.

The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI). The novel, intravenous antiplatelet...

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive antiplatelet medication after percutaneous coronary i...

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombo...

anticoagulation therapy, pulmonary embolism, Couturaud, discontinuation
Among patients with a first episode of pulmonary embolism who received six months of anticoagulant treatment, an additional 18 months of treatment with...
The Medicines Company, Angiomax, generic launch, Sandoz Inc.
The Medicines Company announced an agreement July 9 with Sandoz Inc. for the distribution of an authorized generic of Angiomax (bivalirudin) for...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company in its bivalirudin (Angiomax) patent...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to discharge patients experiencing a...
The Medicines Company, Angiomax, generic launch, Sandoz Inc.
The Medicines Company announced an agreement with Sandoz Inc. for the distribution of an authorized generic of Angiomax (
Cangrelor (Kengreal) from The Medicines Company is a novel intravenous antiplatelet agent indicated as an adjunctive therapy to...
Ticagrelor (Brilinta) 90 mg tablets from AstraZeneca now have FDA approval to be crushed and administered in water by swallowing or via...
The Watchman left atrial appendage closure device from Boston Scientific Corp. is a catheter-delivered heart implant designed to close the...

Articles

platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB
Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control...
cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive...
Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose...
antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI
A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients...

Video Center

Here are a few observations on cardiovascular ultrasound advances I made while attending the 2015...
4 weeks 1 day ago
The latest advances in cardiovascular echocardiography will be presented at the 2015 American...
6 weeks 4 days ago
There were several technology takeaway messages for the future of electrophysiology (EP) at the...
9 weeks 4 days ago
Centricity, webinar, ZFV, ZFP, viewer, remote viewing system, enterprise
Healthcare organizations are demanding more capabilities for image viewers accessed by clinicians. Zero footprint (ZFP) viewers provide imaging tools from...
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...

Comparison Charts

Sorry there is no data available